Stock Surges Following Positive Clinical Update
Shares of Design Therapeutics (NASDAQ:DSGN) climbed 27% on Monday after the company released favorable four-week data from its RESTORE-FA clinical trial evaluating DT-216P2 in patients with Friedreich ataxia.
The biotechnology company said the treatment produced dose-dependent improvements across several clinical measurements while also increasing endogenous frataxin mRNA and protein levels after four weeks of intravenous administration.
According to the company, DT-216P2 was generally well tolerated throughout the study.
Trial Results Show Improvements Across Key Measures
The Phase 1/2 study included 16 patients who completed weekly intravenous treatment with DT-216P2 across dose levels of 0.1, 0.3, 0.6 and 1 mpk over a four-week period as of May 17.
At the highest 1 mpk dose, patients demonstrated average improvements from baseline of 6.4 points on the modified Friedreich’s Ataxia Rating Scale and 2.7 points on the Upright Stability Score.
The therapy also showed improvements exceeding five points on the patient-reported PROMIS Fatigue Scale both at the end of treatment and two weeks after the final dose.
The company noted that this surpassed the three-point threshold commonly viewed as a clinically meaningful improvement in fatigue symptoms.
Frataxin Levels Increased During Treatment
Whole blood FXN mRNA levels rose 65% from baseline in patients receiving the 1 mpk dose after four weeks of therapy.
Design Therapeutics also reported dose-dependent increases in endogenous FXN levels across multiple mRNA and protein assays conducted in whole blood, as well as FXN mRNA measurements taken from affected muscle tissue.
Safety Profile Remains Favorable
The company said no serious adverse events or treatment discontinuations occurred during the study.
All reported side effects were classified as either mild or moderate in severity.
Among adverse events considered possibly or probably related to DT-216P2, mild-to-moderate transient alanine transaminase elevations were observed in three patients.
Company Plans Registrational Pathway Update
Following the positive trial data, Design Therapeutics said it plans to pursue a potential registrational pathway for DT-216P2.
The company expects to provide additional details regarding its regulatory strategy during the fourth quarter of 2026.